Tasidotin hydrochloride
Code | Size | Price |
---|
TAR-T16997-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T16997-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Tasidotin hydrochloride is a peptide analog of the antimitotic depsipeptide dolastatin 15. Tasidotin hydrochloride is an inhibitor of microtubule assembly and microtubule dynamics.
CAS:
623174-20-9
Formula:
C32H59ClN6O5
Molecular Weight:
643.3
Pathway:
Cytoskeletal Signaling
Purity:
0.98
SMILES:
C([C@@H](N(C([C@@H](NC([C@H]([C@@H](C)C)N(C)C)=O)C(C)C)=O)C)[C@H](C)C)(=O)N1[C@H](C(=O)N2[C@H](C(NC(C)(C)C)=O)CCC2)CCC1.Cl
Target:
Microtubule Associated
References
Garg V, et al. Preclinical analysis of Tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5446-54.
Bai R, et al. Intracellular activation and deactivation of Tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009 Jan;75(1):218-26.